At Sibylla Biotech we enjoy scientific challenges
and we believe in pursuing original ideas.

UPDATE: Our research led to the discovery of a new structural target for the ACE-2 protein. Read more. 

This commitment is reflected in our research. We have developed an innovative protocol for drug discovery called PPI-FIT that allows us to identify drug candidates capable of suppressing the expression of target proteins.

Scientists at Sibylla Biotech exploit the full potential of the PPI-FIT technology by applying a unique, cross-disciplinary workflow ranging from the reconstruction of folding pathways using Sibylla’s exclusive computational technology to the identification of drug candidates by mean of medicinal chemistry schemes, to the full characterization and testing of the therapeutic potentials of these compounds in the biological laboratory, by employing relevant experimental models of disease. In this framework, Sibylla’s research covers a wide area of the typical drug discovery pipeline, from the initial step of target identification up to the pre-clinical development and validation of potential new drugs.

Our clients take advantage of our multidisciplinary expertise and innovative technology for their drug discovery needs.
Sibylla Biotech can provide:
>  3D structures of the folding intermediates
>  identification and modeling of druggable sites exclusively present on such protein conformations.

This information can be used for virtual screening in order to identify small molecules specifically able to bind and stabilize the intermediates, thus interfering on the folding process. Experimental hit validation can be provided by a panel of in vitro assays.
We can also implement customized solutions from the validated hits to follow on to optimized lead identification and pre-clinical candidates selection.